Crispin Semakula
Endocrinology, Diabetes & Metabolism · Minneapolis, MNNPI 1538107214
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $31,210 of the $34,411 with a category attached, or 90.7%. 29 manufacturers reported payments, led by AstraZeneca at 57.1% of the total. Reporting peaked in 2019 at $17,858 and has fallen 99.5% since, to $84 in 2025.
Across 98 payments — averaging $351.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$20K
- Johnson & Johnson$14K
- Ipsen Biopharmaceuticals, Inc$321
- Novo Nordisk$106
- Recordati_rare_diseases_inc.$74
- Abbott$65
- plus $634 from 23 others
Across 8 payments — averaging $3756.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$30K
What the payments were for
- Consulting fees$3751%
- Speaking & faculty fees$31,21091%
- Travel & lodging$1,0673%
- Food & beverage$1,4594%
- Education$3001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 25 | $19,654 |
| Johnson & Johnson | 15 | $13,556 |
| Ipsen Biopharmaceuticals, Inc | 6 | $321 |
| Novo Nordisk | 6 | $106 |
| Recordati_rare_diseases_inc. | 5 | $74 |
| Abbott | 2 | $65 |
| Amgen | 3 | $64 |
| Lilly USA, LLC | 5 | $61 |
| Organon | 2 | $55 |
| Merck | 3 | $53 |
| Boehringer Ingelheim | 3 | $52 |
| Insulet Corporation | 3 | $47 |
| Sanofi-aventis U.S. LLC | 3 | $45 |
| GSK | 2 | $37 |
| Redhill Biopharma Inc. | 1 | $24 |
| Amryt Pharma Holdings Ltd | 1 | $19 |
| Phadia US Inc. | 1 | $19 |
| Intuity Medical Inc | 1 | $18 |
| Lifescan, Inc. | 1 | $17 |
| Bayer | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Botanix SB Inc | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Companion Medical, Inc. | 1 | $14 |
| Ascensia Diabetes Care US Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $13 |
| Almatica Pharma LLC | 1 | $12 |
| Cequr Corporation | 1 | $8 |
| BETA Bionics, Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$34,411 in reported general payments places this provider in the 85th percentile of 120 endocrinology, diabetes & metabolism providers in Minnesota.
See all endocrinology, diabetes & metabolism providers in Minnesota →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 456 | $342,272 |
| JanumetSitagliptin Phos/Metformin Hcl | 286 | $207,803 |
| KerendiaFinerenone | 228 | $173,290 |
| MounjaroTirzepatide | 105 | $128,414 |
| OzempicSemaglutide | 88 | $84,434 |
| FarxigaDapagliflozin Propanediol | 75 | $58,424 |
| InvokanaCanagliflozin | 35 | $27,289 |
| LinzessLinaclotide | 49 | $25,178 |
| RybelsusSemaglutide | 22 | $23,752 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 33 | $23,493 |
| TradjentaLinagliptin | 35 | $22,553 |
| JentaduetoLinagliptin/Metformin Hcl | 28 | $17,273 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $13,023 |
| InvokametCanagliflozin/Metformin Hcl | 14 | $12,882 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $12,436 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Jentadueto | $52 | $382,098519 claims |
| MerckJanumet, Janumet Xr | $53 | $231,295319 claims |
| BayerKerendia | $15 | $173,290228 claims |
| Lilly USA, LLCMounjaro | $61 | $128,414105 claims |
| Novo NordiskOzempic, Rybelsus | $106 | $108,186110 claims |
| AstraZenecaFarxiga | $19,654 | $58,42475 claims |
| Johnson & JohnsonInvokana, Invokamet | $13,556 | $40,17149 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 120 endocrinology, diabetes & metabolism providers in Minnesota.
Other endocrinology, diabetes & metabolism in Minneapolis
- Maria CaramoriMinneapolis$147K
- Ameer KhowajaMinneapolis$28K
- Takako ArakiMinneapolis$12K
- Marvin RiosMinneapolis$5K
- Elizabeth SeaquistMinneapolis$4K
- Lisa FishMinneapolis$1K
- Sreekant AvulaMinneapolis$1K
- Richard BergenstalSt Louis Park$595K
- Farha KhanCoon Rapids$349K
- Mark HolmSaint Cloud$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.